KYTX Kyverna Therapeutics, Inc.
$5.63▲ +6.83%
Healthcare
Other
After hours
$5.62▼ -0.18%
Oct 27, 4:01 PM ET
Volume 916.6K
Avg Volume (10D) 861.1K
Key Metrics & Fundamentals
Market Cap
$348.18M
P/E Ratio
–
Div Yield
0.00%
52W Range
5.16 - 13.67
% vs 50 MA
-20.34%
% vs 200 MA
-30.77%
RSI-14
38.9
MACD Histogram
+0.0000
Beta (1Y vs SPY)
2.16
Free Cash Flow
-$40.85M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$37.21M
COGS
–
Operating Exp
$39.56M
Operating Income
-$39.56M
EBIT
-$39.56M
Pretax Income
-$38.32M
Net Income
-$38.32M
EPS (Diluted)
-0.63
Price & Volume History
Loading chart…
Recent News
Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026
GlobeNewswire · Oct 23, 2026 10:30 AM ET
Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto
GlobeNewswire · Oct 21, 2026 7:15 AM ET
Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026
GlobeNewswire · Oct 7, 2026 8:00 AM ET
BioMarin Appoints Cara Bauer as Chief People Officer
PR Newswire · Oct 5, 2026 4:05 PM ET
KYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data — But CEO Says Disease Burden Justifies A Premium Price
Stocktwits · Sep 24, 2026 2:28 PM ET
Kyverna stock jumps on positive one-year therapy data
Investing.com · Sep 24, 2026 10:05 AM ET
Kyverna Reports One-Year Miv-Cel Data From SPS and gMG Trials
InvestorsHub · Sep 24, 2026 6:39 AM ET
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
GlobeNewswire · Sep 24, 2026 6:00 AM ET
Kyverna Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire · Sep 2, 2026 4:05 PM ET
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
BioPharma Dive · Sep 2, 2026 8:32 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See KYTX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.